Contera Pharma elected new executive management team

  • Tuesday, December 01, 2020

  • Contera Pharma, a subsidiary of Bukwang, announced that it elected Dr. Thomas Sager as CEO while further expanding the executive management team to include representatives for Business Development and R&D

  • - Chief Executive Officer; Thomas Sager, PhD.
    - Chief Business Officer; Anders Brandt Elvang, PhD.
    - Chief Science Officer; Kenneth Vielsted Christensen, PhD.

  • Thomas Sager, received his PhD in Neuroscience from University of Copenhagen in 1997. He has more than 20 years of pharma industry experience, mainly from working at Lundbeck A/S, a company specialized in developing and commercializing treatments for diseases of the central nervous system. At Lundbeck, Thomas Sager served in various leadership roles in R&D, while he since 2012 has been working in Business Development and was Vice President, Head of Business Development, Licensing and Scientific Assessment until Nov. 2020.

  • Contera Pharma also elected Dr. Anders Brandt Elvang (PhD), who was former Senior Director, Business Development & Strategy at Lundbeck, as a CBO, and Dr. Kenneth Vielsted Christensen (PhD) who was former Research Program Director at Servier (France) as a Chief Science Officer. Together, they bring substantial CNS experience, including science and business expertise, to Contera Pharma.

  • Contera Pharma has several programs in its development pipeline, including the lead program, JM-010, which is currently under development for treating dyskinesia in Parkinson’s disease. The company recently raised 51 billion KRW (38m EUR) in a Series B financing round to go public on the KOSDAQ. Proceed from the financing will be used to accelerate the currently ongoing US and EU Phase 2 clinical studies in Parkinson’s disease dyskinesia. In addition, it will also be used to accelerate the preparation for the Contera Pharma listing in the KOSDAQ market.

  • Bukwang’s representative said “Contera is a company with significant competitive and technological advantage. It is currently having ongoing Phase 2 clinical studies not only in the EU but also in the US. In addition, the preparation for the Contera listing has been very positive and on the right track so far. All of these factors play an important key role in the success of current recruitments”.

    Contera Pharma, subsidiary of Bukwang, raises 51 billion KRW in Series B financing round

  • Wednesday, July 22, 2020

  • Contera Pharma (“Contera”), subsidiary of Bukwang Pharmaceutical (“Bukwang”), announced 51 billion KRW Series B financing from Korean institutional investors. The size of the current round has increased more than 17-fold compared to series A financing in 2019.

  • Contera, is focused on developing innovative drugs for the treatment of debilitating central nervous system (CNS) disorders. The company has several programs in its development pipelines, including the lead program, JM-010, which is currently under development for treating dyskinesia in Parkinson’s Disease.

  • Contera’s existing investor, Medici Investments (“Medici”), has valued the success potential of the company’s programs highly, and has decided to participate in the current series B round where Contera will receive 51 billion KRW (appr. 275 mio DKK).

  • Proceed from the financing will be used to accelerate the currently ongoing US and EU phase 2 clinical studies in Parkinson’s disease dyskinesia. In addition, it will also be used to accelerate the preparation for Contera listing in the KOSDAQ market.

  • Since last year series A financing, Denmark has been designated as a qualified country for listing and the listing requirements have now been established. In addition, Contera has also established a Korean Branch Office, and core R&D personnel has also been recruited and strengthened to progress the clinical development activities and to prepare the listing.

  • Bukwang’s representative said “Contera is a company with significant competitive and technological advantage. It is currently having ongoing phase 2 clinical study not only in the EU but also in the US. In addition, the preparation for the Contera listing has been very positive and on a right track so far. All of these factors play an important key role in the success of current financing.”

    Contera Pharma opens office in Seoul, Korea

  • Wednesday, Apil 01, 2020

  • To strengthen its activities Contera Pharma has today opened an office in Seoul, Korea. The Seoul office will be headed by Minchang Kwon, Managing Director and Jai Hong Kwon, CFO.

  • John Bondo Hansen, CEO says: Our new Seoul office will be a valuable addition to the Contera organization. I warmly welcome Minchang Kwon and Jai Hong Kwon and look forward to our future collaboration to develop Contera and its projects.

    Bukwang receives US FDA approval for JM-010 phase 2 clinical study IND

  • Friday, February 14, 2020

  • Contera Pharma is preparing for public offering in KOSDAQ


  • Bukwang has recently received the investigational new drug (IND) clearance from the US Food and Drug Administration (FDA) to proceed with phase 2 clinical study of JM-010.

  • JM-010, originating from a Danish bioventure company Contera Pharma, is currently under development for treating dyskinesia which emerges in up to 90% of Parkinson's disease patients following long term treatment of levodopa. Following acquisition of Contera Pharma by Bukwang in 2014, the clinical development activity has been continuously progressing with the completion of clinical proof of concept study in 2016, completion of phase 1 clinical study in 2017, approval of Clinical Trial Application (CTD) for phase 2 European study in 2018 followed by enrollment of patient in the study and then finally recent IND clearance for phase 2 US study from the FDA.

  • The phase 2 US clinical study will enroll 190 dyskinetic Parkinson's disease patients receiving levodopa-based therapy from approximately 30 sites across the country. The clinical study will assess antidyskinetic efficacy as well as safety and tolerability of JM-010.

  • Another phase 2 clinical study with different protocol is currently ongoing in Europe, including Germany, France, and Spain. The results from these two phase 2 clinical studies (US and EU) will be a basis for determining safe and effective dosing regimen for future phase 3 clinical study.

  • Bukwang's representative mentioned "based on consultation with the FDA through pre-IND meeting, the study design and the dosing regimens have been carefully determined and the protocol has been carefully written to make sure the agency' recommendations and Bukwang's strategy are inline. With the FDA IND clearance, JM-010 clinical development will be accelerated to provide effective treatment for patients suffering from debilitating Parkinson's disease dyskinesia.

  • Additionally, Contera Pharma is currently preparing to go public, with Mirae Asset Daewoo as the underwriter for the planned 2021 initial public offering (IPO) in KOSDAQ. Provided the IPO is successful, Contera Pharma is expected to be the first European company listed in the domestic market. With its good performance and the lead candidate now in the late clinical stage, Contera Pharma plans to go public through ‘technology growth company’ track with KOSDAQ.

  • Having the global clinical development activities and IPO process now in place, boost confidence that Bukwang’s open innovation approach is on the right track.

    Bukwang initiates dosing of JM-010 in Europe phase 2 study

  • Friday, January 10, 2020

  • Bukwang Pharmaceutical Co., Ltd. (Bukwang) announced that JM-010 has been administered to the first patient in phase 2 study in Europe.

  • In late 2019, Bukwang successfully initiated phase 2 clinical study of JM-010, which is being developed to treat dyskinesia in Parkinson’s disease, in a number of European countries, and the progress is cruising as company expected.

  • JM-010 is a new drug candidate developed by Bukwang’s subsidiary, Contera Pharma, Copenhagen based CNS focused bioventure, to treat dyskinesia in Parkinson’s disease patients. Dyskinesia is an inevitable symptom that occurs to ~90% of patients who take levodopa.

  • Currently, there is no treatment available in Europe, therefore not only investigators but also patients show strong interest in this clinical study.

  • Bukwang representative said, “Beginning with the first patient dosing, the company will speed up the clinical study by enrolling more patients, and eventually make LID treatment available to Parkinson’s patients.”

  • JM-010 phase 2 clinical study in Europe is cruising, and expecting to have results in 2021.